|Dr. James A. Campbell Ph.D., MBA||Chief Exec. Officer, Managing Director and Director||220k||N/A||N/A|
|Ms. Melanie Jaye Leydin B.Bus (Acc/Law), CA||Company Sec.||60k||N/A||44|
|Dr. Deanne Greenwood Ph.D., MBA||VP of Bus. Devel. & Intellectual Property||N/A||N/A||N/A|
|Ms. Valentina Dubljevic MBB, BSc||VP of Scientific & Clinical Devel.||N/A||N/A||N/A|
Patrys Limited, together with its subsidiaries, develops natural human antibody-based therapeutic products for the treatment of cancer in Australia. The companys clinical products include PAT-SM6, a natural human antibody used for the treatment of various types of cancer, including solid tumors, such as melanoma, breast, colon, and pancreatic, as well as blood-based cancers that include multiple myeloma; and PAT-SC1, an antibody for treating gastric cancer. Its late stage preclinical products comprise PAT-LM1, a natural human antibody, which is used in the treatment of colon, lung, breast, ovary, and pancreatic cancers; and Deoxymab 3E10 a novel autoantibody that penetrates cancer cell nuclei, damage DNA, inhibit DNA repair, and kill DNA repair-deficient cancer cells. The company was founded in 2006 and is based in Melbourne, Australia.
Patrys Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.